Effect of one-stop hybrid coronary revascularization on postoperative renal function and bleeding: A comparison study with off-pump coronary artery bypass grafting surgery  by Zhou, Shan et al.
Zhou et al Acquired Cardiovascular DiseaseEffect of one-stop hybrid coronary revascularization on postoperative
renal function and bleeding: A comparison study with off-pump
coronary artery bypass grafting surgeryShan Zhou, MD,a Zhongrong Fang, MD,a Hui Xiong, MD,b Shengshou Hu, MD,b Bo Xu, MD,c
Lei Chen, MD,a and Weipeng Wang, MDaFrom th
Labo
vascu
Colle
Disclos
Receive
for pu
Address
Hosp
1000
0022-52
Copyrig
http://dx
A
C
DObjectives: Although 1-stop hybrid coronary revascularization offers potential benefits for selected patients
with multivessel coronary artery disease, the exposure to contrast dye and potent antiplatelet drugs could
increase the risk of postoperative acute kidney injury and coagulopathy. The goal of the present study was to
compare the measures of renal function, postoperative bleeding, and transfusion requirements in patients under-
going hybrid revascularization compared with off-pump coronary artery bypass grafting (CABG).
Methods:We retrospectively analyzed the data from 141 consecutive patients who had undergone 1-stop hybrid
coronary revascularization from June 2007 to January 2011. Propensity score matching with 141 off-pump
CABG patients from our surgical database was performed for comparison. The change in renal function, cumu-
lative chest tube drainage, and clinical outcome parameters were compared between the 2 groups.
Results: Compared with off-pump CABG, patients undergoing hybrid revascularization had significantly less
chest tube drainage at 12 hours after surgery (P ¼ .04) and for the total amount during the postoperative period
(P<.001) and required fewer blood transfusions (P ¼ .001). The hybrid group had a higher incidence of acute
kidney injury, but this did not reach statistical significance (25.2% vs 17.6%, P ¼ .13). The hybrid group
required less inotropic and vasoactive support, had fewer respiratory complications, required a shorter time
of mechanical support, and had a decreased length of intensive care unit stay.
Conclusions: Compared with off-pump CABG, 1-stop hybrid coronary revascularization was associated with
benefits such as less postoperative bleeding and blood transfusion requirements without significantly increasing
the additional risk of acute kidney injury. (J Thorac Cardiovasc Surg 2014;147:1511-6)Supplemental material is available online.
Hybrid coronary revascularization (HCR) has been defined
as the combination of minimally invasive direct coronary
artery bypass surgery and percutaneous coronary interven-
tion (PCI) in selected patients with multivessel coronary ar-
tery disease.1-4 The potential advantages of HCR include
the superior long-term patency of the surgical left internal
mammary artery (LIMA) to left anterior descending artery
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The Journal of Thoracic and Carwith drug-eluting stents instead of saphenous vein grafts
for non-LAD lesions.8-10 The term ‘‘1-stop HCR’’ has
been used when the 2 procedures have been performed
consecutively in the same setting, typically referred to as
a ‘‘hybrid operating room.’’11,12 The suggested benefits
of this new approach include improved efficiency and
logistics, immediate angiographic confirmation of graft
patency, and greater patient satisfaction.2,13 The potential
risks of 1-stop HCR have been associated with the adminis-
tration of potent antiplatelet drugs and exposure to contrast
dye, raising concerns about coagulopathy and increased
transfusion requirements and renal insufficiency, respec-
tively. The goal of the present study was to examinewhether
1-stop HCR increases the risk of postoperative bleeding
and renal insufficiency compared with off-pump coronary
artery bypass grafting (OPCABG).METHODS
Patient Selection
After institutional review board approval, we retrospectively collected
data from 141 consecutive patients who had undergone 1-stop HCR at
our institution from June 2007 to January 2011. Propensity score matching
was used to select 141 patients from 3256 OPCABG patients with data
recorded in our surgical database during the same period. The parameters
used for matching were selected in accordance with the data readilydiovascular Surgery c Volume 147, Number 5 1511
Abbreviations and Acronyms
AKI ¼ acute kidney injury
HCR ¼ hybrid coronary revascularization
ICU ¼ intensive care unit
LAD ¼ left anterior descending coronary artery
LIMA ¼ left internal mammary artery
OPCABG ¼ off-pump coronary artery bypass
grafting
PCI ¼ percutaneous coronary intervention
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D available in our database: gender, age, body mass index, preoperative arte-
rial hypertension, hyperlipidemia, diabetes mellitus, preoperative myocar-
dial infarction, and left ventricular ejection fraction (Table 1). Additional
parameters were collected and compared between the 2 groups after the
primary matching process (Table 2).
The inclusion criteria for 1-stop HCR were the presence of multivessel
coronary lesions demonstrated by coronary angiography, which involved
a LAD lesion (or lesions) that was judged not suitable for PCI butwas a suit-
able target for surgical grafting (eg, chronic total occlusion, severe calcifi-
cation, ostial lesion, or proximal lesions) and non-LAD lesions that were
suitable for PCI. Patients with previous sternotomy, LIMA stenosis, symp-
toms of congestive heart failure, or unstable hemodynamics (eg, preopera-
tive pharmacologic or mechanical support), the need for concomitant
cardiac surgery (eg, valve replacement or repair procedure), and patients
with contradictions for PCI (eg, allergy to contrast dye) were excluded.
Procedure
A balanced general anesthesia technique with midazolam, etomidate or
propofol, fentanyl or sufentanil, and vecuronium was used for induction,
and a potent inhalational-based agent or propofol infusion were used for
anesthesia maintenance.
For the 1-stop hybrid procedure, the patients first underwent minimally
invasive direct coronary artery bypass surgery using a midline ministernot-
omy approach, followed by PCI for non-LAD lesions. Technically,
a reversed-J inferior sternotomy was performed up to the left second inter-
costal space, and the LIMA was harvested with the assistance of a lift
retractor under direct vision. Unfractionated heparin (100-120 IU/kg
body weight) was administered before harvesting the LIMA. Surgical anas-
tomosis of the LIMA to LAD graft was performed using a stabilizer
(Octopus,Medtronic Inc, Minneapolis, Minn) on the beating heart. Patients
who did not tolerate OPCABG because of unstable hemodynamics were
converted to on-pump surgery. After surgical LIMA to LAD anastomosis
and chest closure, angiography was performed to confirm the patency of
the LIMA-LAD graft. If any angiographic defects were identified, surgical
revision was immediately performed. For the PCI procedure, access was
established through the femoral artery using a previously described
standard technique.14
For the OPCABG procedure, a median sternotomy was performed in all
patients. The LIMA and saphenous vein conduits were harvested under
direct vision. The distal anastomoses of the LIMA to LAD and saphenous
conduits to non-LAD target grafts were performed on the beating heart
using a stabilizer (Octopus). The proximal anastomoses were accom-
plished with a partial occluding aortic clamp. Transonic flow measure-
ments (Medi-Stim Butterfly System BF2004; Medi-Stim AS, Oslo,
Norway) were performed in all patients to confirm graft patency after
revascularization.
Anticoagulation Protocol
Details about the anticoagulation and, specifically, the antiplatelet
regimen for hybrid procedures practiced in our institution have been1512 The Journal of Thoracic and Cardiovascular Surpreviously published.15 Aspirin 100 mg once daily was continued until
the morning of surgery, and clopidogrel was discontinued 5 to 7 days
before surgery. Unfractionated heparin (100-120 IU/kg body weight) was
administered intraoperatively to achieve an activated clotting time>300
seconds during the surgical procedure. After completion of the LIMA to
LAD anastomosis, heparin was reversed with protamine sulfate in accor-
dance with the results from a heparin-protamine titration assay. A loading
dose of 300 mg clopidogrel was administered through a nasogastric tube
before the PCI procedure. Additional heparin (100 IU/kg body weight)
was administered if the activated clotting time was<200 seconds during
the PCI procedure. The maintenance antiplatelet regimen after the proce-
dure consisted of 75mg clopidogrel once daily for12months, and aspirin
300 mg once daily for the first 30 days, followed by 100 mg aspirin once
daily for life.
For the OPCABG procedure, aspirin and clopidogrel were discontin-
ued5 days before surgery. Also, 200 IU/kg body weight of unfractionated
heparin was administered before harvesting the LIMA. Additional heparin
was administered to maintain the activated clotting time>300 seconds
throughout the whole procedure. After completion of all anastomoses,
heparin was fully reversed with protamine sulfate.
Data Collection
The primary endpoints of the present study were to compare the inci-
dence of postoperative bleeding and transfusion requirements and renal
function between the 2 groups. Postoperative chest tube drainage was
measured at 6 and 12 hours after the procedure, and the total cumulative
chest tube drainage was recorded for the whole postoperative period.
Serum creatinine was compared between the 2 groups for the first 3 post-
operative days. If more than 1 serum creatinine value was available each
day, the highest value was chosen for analysis. Acute kidney injury (AKI)
was defined according to the Acute Kidney Injury Network criteria: serum
creatinine increase 26.5 mmol/L or an increase to 1.5-fold from baseline
within 48 hours.16
The secondary endpoints were defined as the following postoperative
clinical outcomes: mortality during the hospital stay, hemodynamic insta-
bility requiring the use of an intra-aortic balloon pump, hemodialysis, myo-
cardial damage (defined as an increase in serum creatinine kinase to>5
times the upper normal limit17), new-onset atrial fibrillation, mechanical
ventilation duration, respiratory insufficiency requiring endotracheal
reintubation, abnormal postoperative chest radiographic findings such as
atelectasis and pleural effusion, neurologic complications (eg, stroke or
transient ischemia attack), emergency reoperation and resternotomy, length
of stay in the intensive care unit (ICU), and postoperative hospital length of
stay. Hemodynamic stability was assessed using the following 3 categories:
hemodynamically stable (no vasoactive or inotropic drug administration),
moderate hemodynamic instability (1-2 drugs), and unstable when>3
drugs were required intraoperatively or during the postoperative period
in the ICU.
Statistical Analysis
Propensity score matching was performed using Statistical Analysis
Systems software for Windows, version 9.2 (SAS Institute Inc, Cary,
NC). A predesigned SAS macro programwas used for the propensity score
algorithm, using an interval score<0.01 between the 2 groups to define
a qualified match. If more than 1 OPCABG case was matched to a hybrid
case, random selection was performed using the macro program.
The data are expressed as the mean  standard deviation, median, or
percentage. For continuous variables, the Student t test was used tomeasure
the differences with a normal distribution and the Wilcoxon rank sum test
was used for variables not normally distributed. Categorical variables were
compared using the chi-square statistic or Fisher’s exact test. Analysis
of variance for repeated measures was used to measure differences
between the measurement points (original data presented in Table E1).
P values < .05 were considered statistically significant. All statisticalgery c May 2014
TABLE 1. Baseline variables used for propensity matching
Variable
Hybrid
(n ¼ 141)
OPCABG
(n ¼ 141) P value
Male gender 125 (88.7) 126 (89.4) .85
Age (y) 62  10.1 63.2  8.5 .36
BMI (kg/m2) 25.9  4.2 25.8  2.8 .85
Arterial hypertension 91 (64.5) 78 (55.3) .11
Diabetes mellitus 37 (26.2) 45 (31.9) .29
Hyperlipidemia 76 (53.9) 62 (44) .10
Previous myocardial
infarction
46 (32.6) 60 (42.6) .09
LVEF (%) 61.83  6.9 60.1  9.3 .07
Data are presented as n (%) or mean  standard deviation. Hybrid, One-stop hybrid
coronary revascularization; OPCABG, off-pump coronary artery bypass grafting;
BMI, body mass index; LVEF, left ventricular ejection fraction.
FIGURE 1. Postoperative bleeding in patients undergoing 1-stop hybrid
coronary revascularization (hybrid) compared with off-pump coronary
artery bypass grafting (OPCABG). *P value refers to the comparison
between the 1-stop hybrid coronary revascularization and OPCABGgroups.
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software package for Windows, version 16.0 (SPSS, Chicago, Ill).
RESULTS
All 141 patients in each group successfully underwent
coronary revascularization. Of the patients in the hybrid
group, 3 required conversion to on-pump LIMA to LAD
graft anastomosis because of intraoperative hemodynamic
instability. The baseline parameters were not statistically
different between the 2 groups (Tables 1 and 2).
No significant difference was found in the amount of
chest tube drainage between the 2 groups at 6 hours after
surgery; however, the hybrid group had significantly less
drainage at 12 hours (P ¼ .04) and less total cumulative
postoperative chest tube drainage overall (P < .001)
(Figure 1). Additionally, the hybrid group had significantlyTABLE 2. Unmatched baseline variables
Variable
Hybrid
(n ¼ 141)
OPCABG
(n ¼ 141) P value
Previous PCI 14 (9.9) 16 (11.3) .70
Smoking history 78 (55.3) 70 (49.6) .34
COPD 7 (5) 7 (5) 1.0
EuroSCORE 2.34  2.24 2.6  2.16 .33
Chronic renal insufficiency 3 (2.1) 3 (2.1) 1.0
Preoperative creatinine
(mmol/L)
90.3  22.4 84  17.9 .08
Previous cerebrovascular
disease
13 (9.2) 21 (14.9) .14
Peripheral vascular disease 31 (22) 34 (24.1) .67
LM disease 33 (23.4) 47 (33.4) .09
LAD disease 141 (100) 140 (99.3) 1.0
LCx disease 92 (65.2) 127 (90) <.001
RCA disease 107 (76) 121 (85.8) .05
b-Blocker medication 129 (91.5) 126 (89.4) .54
Data are presented as n (%) or mean  standard deviation. PCI, Percutaneous coro-
nary intervention; COPD, chronic obstructive pulmonary disease; EuroSCORE,
European system for cardiac operative risk evaluation; LM, left main coronary artery;
LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery;
RCA, right coronary artery; Hybrid, one-stop hybrid coronary revascularization;
OPCABG, off-pump coronary artery bypass grafting.
The Journal of Thoracic and Carlower packed red blood cell and plasma transfusion rates
compared with the OPCABG group (21.3% vs 31.9%,
P ¼ .04, and 9.9% vs 31.2%, P<.001, respectively). No
difference was found in the rate of platelet transfusion be-
tween the 2 groups (Table 3).
The serum creatinine levels increased significantly after
surgery but showed a decreased tendency at ICU admission
in both groups. The serum creatinine levels were higher
in the hybrid group than in the OPCABG group at ICU
admission (P ¼ .02, Figure 2), although none of the other
measurement points showed significant differences. When
applying the Acute Kidney Injury Network criteria to
both groups, the hybrid group had a higher rate of acute kid-
ney injury compared with the OPCABG group, but this did
not reach statistical significance (25.2% vs 17.6%, P¼ .13;
Table 3). None of the patients in the hybrid group and
2 patients in the OPCABG group required hemodialysis
for acute renal dysfunction.
The secondary outcomes measures are presented in
Table 3. Intraoperatively, the hybrid group had significantly
longer anesthesia and surgical times but fewer inotropic drug
requirements (Table 3). Postoperatively, 1 patient died of
cardiac arrest in the hybrid group, and 2 patients died of post-
operative multiorgan dysfunction in the OPCABG group.
The patients who underwent the 1-stop hybrid procedure
had fewer pulmonary complications (atelectasis and/or pleu-
ral effusion on the chest radiograph), fewer vasoactive and
inotropic drug requirements, required lessmechanical venti-
lation, and a shorter ICU length of stay compared with
the OPCABG group (Table 3). No significant differences
were found in the postoperative hospital length of stay,
intra-aortic balloon pump requirement, myocardial damage
determined by creatinine kinase, reoperation, endotrachealdiovascular Surgery c Volume 147, Number 5 1513
FIGURE 2. Serum creatinine in patients undergoing 1-stop hybrid coro-
nary revascularization compared with off-pump coronary artery bypass
grafting (OPCABG) patients. *P value refers to comparison between
1-stop hybrid coronary revascularization and OPCABG. POD, Postopera-
tive day.
TABLE 3. Intraoperative and postoperative clinical outcomes
between hybrid and OPCABG groups
Variable
Hybrid
(n ¼ 141)
OPCABG
(n ¼ 141) P value
Intraoperative comparison
Anesthesia time (min) 304.5  75.5 239.4  43.2 <.001
Operative time (min) 248.5  73.4 199.4  43.2 <.001
Urine output (mL) 639.2  484 349.8  265.6 <.001
Fluid infusion (mL) 1167.2  453 1324.8  440 .003
Intraoperative vasoactive
drugs (n)
.005
0 26 (18.4) 11 (7.8)
1-2 115 (81.5) 126 (89.4)
>3 0 (0) 4 (2.8)
Postoperative comparison
Mortality 1 (0.71) 2 (1.41) 1.0
IABP 0 (0) 2 (1.41) .50
Myocardial damage 5 (3.5) 7 (5.4) .45
Dialysis 0 (0) 2 (1.41) .50
Acute kidney injury 35 (25.2) 23 (17.6) .13
Reoperation 4 (2.8) 8 (5.6) .24
Reintubation 2 (1.41) 1 (0.71) 1.0
Neurologic event 1 (0.71) 1 (0.71) 1.0
Atelectasis 25 (17.7) 54 (38.3) <.001
Pleural effusion 8 (5.7) 19 (13.5) .03
New-onset atrial
fibrillation
24 (17) 14 (9.9) .08
Mechanical ventilation
time (h)
12.9  11 18.3  18.2 .003
ICU stay (h) 34.8  33.1 45.6  37.3 .01
Postoperative hospital
stay (d)
8.19  2.54 8.49  3.53 .41
ICU vasoactive drugs (n) .04
0 0 (0) 1 (0.71)
1-2 113 (80.1) 95 (67.4)
>3 28 (19.9) 45 (31.9)
Packed RBC transfusion
rate
30 (21.3) 45 (31.9) .04
Plasma transfusion rate 14 (9.9) 44 (31.2) <.001
Platelet transfusion rate 1 (0.7) 3 (2.1) .62
Data are presented as mean standard deviation or n (%). IABP, Intra-aortic balloon
pump; ICU, intensive care unit; RBC, red blood cells; Hybrid, one-stop hybrid
coronary revascularization; OPCABG, off-pump coronary artery bypass grafting.
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logic events between the 2 groups.DISCUSSION
One-stop HCR offers potential benefits for patients
presenting for complex coronary revascularization.3,18,19
Concerns have been raised, however, about an increased
risk of postoperative bleeding and renal dysfunction with
this approach.2,20 The findings from the present study
have suggested that 1-stop HCR did not increase the risk
of postoperative bleeding and renal dysfunction compared
with OPCABG surgery. Although exposed to a potent1514 The Journal of Thoracic and Cardiovascular Surantiplatelet drug regimen, the hybrid patients actually had
less bleeding and required fewer blood transfusions com-
pared with the OPCABG group.
The results of decreased postoperative bleeding and
transfusion requirements might have resulted from the
less invasive nature of the hybrid approach.19 Fewer surgi-
cal anastomoses are needed because of stent placement, and
a smaller surgical incision is typically used for the mini-
mally invasive direct coronary artery bypass approach in
the hybrid group compared with the complete midline ster-
notomy in the OPCABG group. However, the optimal anti-
platelet regimen for patients undergoing HCR has not been
established. Some studies have adopted 600 mg clopidogrel
in HCR setting21,22; however, despite better inhibition of
platelet activity, postoperative excessive bleeding poses
a major concern. The goal of antiplatelet therapy for
patients undergoing HCR is to inhibit platelet activity to
preserve stent patency and to minimize the risk of
postoperative bleeding. Although controversial at first, the
specific choice of antiplatelet drugs and the exact timing
of drug administration are crucial and could explain some
of the controversial findings from previous studies. Our
result of decreased postoperative bleeding after HCR
correlated with the findings from Reicher et al,11 who
administered 300 mg clopidogrel on ICU arrival. Zhao
et al4 found no difference in postoperative chest tube drain-
age when conventional CABG surgery was compared with
HCR, which included the administration of 300 mg clopi-
dogrel before entering the operating room. These data
suggest that for patients undergoing HCR, high-dose clopi-
dogrel given after the surgical part of the procedure might
have less effect on hemostasis compared with preoperative
drug administration.23
In our study, the contrast dye used for the interventional
part of the hybrid procedure was not associated with renal
dysfunction. Both cardiac surgery and the administrationgery c May 2014
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risk of renal dysfunction.24,25 We had hypothesized that
the incidence of acute kidney injury would be greater
in patients undergoing HCR compared with those
undergoing OPCABG alone. Previous investigations have
reported controversial findings. Kon et al3 reported a lower
rate of postoperative renal insufficiency after HCR com-
pared with OPCABG (0% vs 10%), defined as an increase
in creatinine of>25% greater than baseline, and Halkos
et al26 found no difference in renal failure between HCR
and OPCABG. The different outcome definitions could
partly explain the inconsistent results. Zhao et al4 reported
no significant differences in serum creatinine values within
3 days after surgery between the 2 groups; however, their
entire cohort underwent intraoperative completion angiog-
raphy, increasing the risk of AKI for both groups. In the
present study, we observed a slightly greater AKI rate com-
pared with that after OPCABG, but the difference not reach
statistical significance, and the serum creatinine levels did
not differ significantly between the 2 groups during the
observed study period. The reason could be that the more
stable hemodynamics and better urine output in the hybrid
group contributed to the nondetection of differences in
AKI in the present study.27
We also found significantly fewer respiratory complica-
tions, a shorter time required for mechanical ventilation,
and a shorter ICU length of stay in the hybrid group. The
lower atelectasis rate in the hybrid group might have been
related to the minithoracotomy surgical approach,28 and
the higher pleural effusion rate in OPCABG group might
have been related to the surgical trauma and more fluid
administration during surgery.
Study Limitations
Amajor limitation of the present study was the retrospec-
tive study design. Additionally, although propensity match-
ing was used, patient selection bias could not be fully
excluded. The relatively small sample size and only short-
term follow-up were additional limitations.
CONCLUSIONS
One-stop HCR did not increase the rate of postoperative
bleeding or AKI compared with OPCABG in our study pop-
ulation. Additional randomized and multicenter studies are
warranted to more conclusively establish the risk and bene-
fits associated with 1-stop HCR.
The authors would like to thank Dr YangWang from the Depart-
ment of Statistics, Fuwai Hospital, Cardiovascular Institute, for his
kindly contribution in statistical work in our study.
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TABLE E1. Serum creatinine in hybrid and OPCABG groups at different measurement points (original data from Figure 2)
Serum creatinine (mmol/L) Hybrid (n ¼ 141) OPCABG (n ¼ 141) P value*
Baseline 90.26  22.4 84  33.4
ICU admission 83.53  14.8 78.68  18.7 .04
POD 1 93.86  20 91.83  28.7 .01
POD 2 99.54  27.6 98.73  23.7 .02
POD 3 96.48  36.4 97.28  38.5 .04
Data are presented as mean  standard deviation. Hybrid, One-stop hybrid coronary revascularization; OPCABG, off-pump coronary artery bypass grafting; ICU, intensive care
unit; POD, postoperative day. *P value refers to comparison with baseline serum creatinine according to repeated measurement results.
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